Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
ADANIENT-ANSE
CPPLUS-ANSE
AEGISLOG-ANSE
PREMIERENE-ANSE
REDINGTON-ANSE
HONASA-ANSE
LLOYDSENT-ANSE
CELLO-ANSE
JSLL-ANSE
SREEL-TNSE
GENPHARMA-XNSE
Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 76% | 315% |
| - | - | 13% | -64% |
| - | -24% | -29% | -32% |
| 3% | 3% | 1% | 1% |
Peer Comparison
Symbol
ADANIENT-A
CPPLUS-A
AEGISLOG-A
PREMIERENE-A
REDINGTON-A
HONASA-A
LLOYDSENT-A
CELLO-A
JSLL-A
SREEL-T
GENPHARMA-X
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 2,710 | ₹365234 Cr | 63.65 | 11.02 | 97.19 | ₹9339 Cr |
| 4,033.8 | ₹49371 Cr | 83.28 | 15.13 | 53.43 | ₹368 Cr |
| 1,189.75 | ₹44400 Cr | 33.33 | 7.42 | 40.69 | ₹898 Cr |
| 838 | ₹37723 Cr | 21.32 | 10.09 | 46.95 | ₹1510 Cr |
| 331.5 | ₹26682 Cr | 14.39 | 6.92 | 26.4 | ₹1490 Cr |
| 527.25 | ₹17272 Cr | 61.09 | 2.24 | 9.99 | ₹200 Cr |
| 61.03 | ₹9779 Cr | 95.38 | 0.09 | 0.89 | ₹283 Cr |
| 369.75 | ₹8198 Cr | 26.53 | 3.63 | 17.5 | ₹332 Cr |
| 299.25 | ₹3765 Cr | 17.56 | 2.95 | 22.03 | ₹222 Cr |
| 263 | ₹637 Cr | 18.69 | 4.27 | 15.29 | ₹29 Cr |
| 1.06 | ₹58 Cr | 25.2 | 0.02 | 0.09 | ₹2 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹86 Cr | ₹50 Cr | ₹55 Cr | ₹40 Cr | ₹33 Cr | ₹12 Cr | ₹14 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹10 Cr | ₹6 Cr | ₹8 Cr | ₹6 Cr |
| ₹1 Cr | ₹37 L | ₹1 Cr | ₹98 L | ₹47 L | ₹70 L | ₹94 L | ₹81 L | ₹75 L | ₹57 L | ₹31 L | ₹14 L | ₹15 L | ₹6 L |
| ₹87 Cr | ₹50 Cr | ₹56 Cr | ₹41 Cr | ₹33 Cr | ₹13 Cr | ₹15 Cr | ₹9 Cr | ₹7 Cr | ₹6 Cr | ₹11 Cr | ₹7 Cr | ₹8 Cr | ₹6 Cr |
| ₹85 Cr | ₹49 Cr | ₹54 Cr | ₹42 Cr | ₹34 Cr | ₹11 Cr | ₹15 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹10 Cr | ₹6 Cr | ₹8 Cr | ₹6 Cr |
| ₹3 Cr | ₹1 Cr | ₹3 Cr | -₹26 L | -₹80,000 | ₹2 Cr | -₹8 L | ₹2 Cr | ₹87 L | ₹75 L | ₹30 L | ₹16 L | ₹11 L | ₹27 L |
| ₹44 L | ₹40 L | ₹48 L | ₹41 L | ₹23 L | ₹12 L | ₹11 L | ₹16 L | ₹7 L | ₹10 L | ₹16 L | ₹50,000 | ₹7 L | ₹6 L |
| ₹2 Cr | ₹26 L | ₹2 Cr | -₹1 Cr | -₹80 L | ₹1 Cr | -₹44 L | ₹1 Cr | ₹50 L | ₹49 L | ₹11 L | ₹3 L | ₹4 L | ₹20 L |
| ₹1 Cr | -₹17 L | ₹1 Cr | -₹83 L | -₹1 Cr | ₹1 Cr | -₹28 L | ₹76 L | ₹70 L | ₹29 L | ₹49 L | ₹6 L | ₹60,000 | ₹1 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹28 Cr |
| ₹11 Cr | ₹10 Cr | ₹9 Cr | -₹12 Cr |
| ₹11 Cr | ₹10 Cr | ₹9 Cr | -₹12 Cr |
| ₹66 Cr | ₹65 Cr | ₹64 Cr | ₹15 Cr |
| -₹62 L | ₹12 L | ₹14 L | ₹0 |
| ₹2 Cr | ₹0 | ₹0 | ₹0 |
| ₹22 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| -₹3 Cr | -₹46 L | -₹43 L | -₹85 L |
| ₹1 Cr | ₹2 Cr | ₹68 L | ₹0 |
| ₹14 L | ₹1 L | ₹0 | ₹0 |
| ₹23 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr |
| — | — | — | — |
| ₹32 Cr | ₹8 Cr | ₹2 Cr | ₹1 Cr |
| ₹7 Cr | ₹1 Cr | ₹32 L | ₹9 L |
| ₹8 Cr | ₹0 | ₹0 | ₹60 L |
| ₹2 Cr | ₹56 L | ₹0 | ₹0 |
| ₹48 Cr | ₹10 Cr | ₹3 Cr | ₹2 Cr |
| ₹136 Cr | ₹79 Cr | ₹71 Cr | ₹19 Cr |
| ₹2 L | ₹2 L | ₹2 L | ₹2 L |
| ₹33 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| — | — | — | — |
| ₹48 Cr | ₹8 Cr | ₹93 L | ₹15 L |
| ₹7 Cr | ₹89 L | ₹10 L | ₹5 L |
| ₹41 Cr | ₹8 Cr | ₹84 L | ₹10 L |
| ₹2 Cr | ₹20 Cr | ₹18 Cr | ₹0 |
| ₹2 Cr | ₹20 Cr | ₹18 Cr | ₹0 |
| ₹12 Cr | ₹24 Cr | ₹11 Cr | ₹0 |
| ₹54 L | ₹2 Cr | ₹0 | ₹0 |
| ₹55 Cr | ₹53 Cr | ₹30 Cr | ₹10 L |
| — | — | — | — |
| ₹0 | ₹0 | ₹2 Cr | ₹95 L |
| ₹14 Cr | ₹7 Cr | ₹9 Cr | ₹10 Cr |
| ₹29 Cr | ₹14 Cr | ₹9 Cr | ₹6 Cr |
| ₹10 Cr | ₹5 Cr | ₹19 Cr | ₹2 Cr |
| ₹82 L | ₹4 L | ₹38 L | ₹2 L |
| ₹27 Cr | ₹21 L | ₹2 Cr | ₹58 L |
| ₹81 Cr | ₹26 Cr | ₹41 Cr | ₹19 Cr |
| ₹33 Cr | ₹17 Cr | ₹38 Cr | ₹17 Cr |
| ₹136 Cr | ₹79 Cr | ₹71 Cr | ₹19 Cr |
| ₹1 | ₹1 | ₹1 | ₹1 |
| ₹1 | ₹1 | ₹1 | ₹0 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹97 L | ₹2 Cr | ₹25 L | ₹28 L |
| ₹2 Cr | -₹1 Cr | ₹39 L | ₹16 L |
| -₹19 Cr | ₹2 Cr | -₹4 Cr | -₹4 Cr |
| -₹17 Cr | ₹3 Cr | -₹3 Cr | -₹3 Cr |
| -₹18 Cr | ₹3 Cr | -₹3 Cr | -₹3 Cr |
| ₹13 Cr | -₹4 Cr | -₹28 Cr | ₹36 L |
| ₹4 Cr | -₹1 Cr | ₹48 Cr | ₹3 Cr |
| -₹37 L | -₹3 Cr | ₹17 Cr | ₹39 L |
| ₹65 L | ₹3 Cr | ₹2 Cr | ₹2 Cr |
| ₹69 L | ₹0 | ₹0 | ₹0 |
| ₹97 L | ₹65 L | ₹19 Cr | ₹2 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 2 out of 9 oscillators
RSI
48.45Neutral
STOCH %K
57.69Neutral
MACD Level(12,26)
0.01Buy
Ultimate Oscillator
46.01Sell
Aroon Oscillator
-76.00Sell
BOP
0.20Buy
CCI
-15.29Neutral
Williams %R
-42.31Neutral
Momentum
0.04Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 8 out of 9 moving averages
EMA 9
1.07Sell
SMA 9
1.09Sell
EMA 21
1.07Sell
SMA 21
1.06Neutral
EMA 50
1.07Sell
SMA 50
1.07Sell
EMA 200
1.19Sell
SMA 200
1.11Sell
WMA 20
1.08Sell
Pivot
Pivot
Classic
Resistance 5
1.22
Resistance 4
1.18
Resistance 3
1.14
Resistance 2
1.10
Resistance 1
1.08
Pivot
1.06
Support 1
1.04
Support 2
1.02
Support 3
0.98
Support 4
0.94
Support 5
0.90
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 32.06% | 29.98% | 29.98% | 29.98% | 29.98% | 29.98% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 67.94% | 70.02% | 70.02% | 70.02% | 70.02% | 70.02% |
Bulk & block deals
Name
Rajesh Mirchumal Sadhwani
Rajesh Mirchumal Sadhwani
Divya Deven Pathak
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 31 Aug 2026 | Purchase | 42 L | ₹1.05 | 40 L | Bulk | 0.722387 | BSE |
| 28 Aug 2026 | Purchase | 50.50 L | ₹1.01 | 50 L | Bulk | 0.902984 | BSE |
| 30 Dec 2024 | Sell | 1.03 Cr | ₹2.95 | 35 L | Bulk | 0.632089 | BSE |
Insider trading & SAST
Client name
Rajesh Sadhwani
Rajesh Sadhwani
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01 Sep 2026 | Promoter and Director | Acquisition | 1.173879 | 15.26 | 71.50 L | ₹1.10 | 65 L | 31 Aug 2026 - 01 Sep 2026 | Market Purchase | 8,45,00,000 | Insider Trading | — | Equity |
| 31 Aug 2026 | Promoter and Director | Acquisition | 0.902984 | 14.09 | 50.50 L | ₹1.01 | 50 L | 28 Aug 2026 | Market Purchase | 7,80,00,000 | Insider Trading | — | Equity |
Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
Adi Rasayan Ltd is engaged in manufacturing and trading in organic and inorganic chemicals dyes and pigments.
Corporate Actions
Date
Type
Details
Company details
Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Genpharmasec Share Price
1.06+0.00 (+0.95%)
-32.48% past 1 Year
News
1 of 20
ResultGENPHARMA3 Nov 2026
NULL
Genpharmasec - Quaterly Results
ResultGENPHARMA21 May 2026
NULL
Genpharmasec reports Profit after tax of 2.32 Crores, in the March 2026 quarter
ResultGENPHARMA21 May 2026
NULL
Genpharmasec informs about directors meeting
Stock NewsGENPHARMA24 Mar 2026
NULL
Genpharmasec - Quaterly Results
ResultGENPHARMA9 Feb 2026
NULL
Genpharmasec reports Profit after tax of 75.50 Lakhs, in the December 2025 quarter
ResultGENPHARMA9 Feb 2026
NULL
Genpharmasec informs about confirmation certificate
Stock NewsGENPHARMA6 Jan 2026
NULL
Genpharmasec informs about trading window closure
Stock NewsGENPHARMA26 Dec 2025
NULL
Genpharmasec reports Profit after tax of 81.50 Lakhs, in the September 2025 quarter
ResultGENPHARMA6 Nov 2025
NULL
Genpharmasec informs about trading window closure
Stock NewsGENPHARMA24 Sept 2025
NULL
Genpharmasec informs about press release
Stock NewsGENPHARMA6 Sept 2025
NULL
Genpharmasec informs about board meeting
Stock NewsGENPHARMA28 Aug 2025
NULL
Genpharmasec informs about press release
Stock NewsGENPHARMA8 Aug 2025
NULL
Genpharmasec - Quaterly Results
ResultGENPHARMA7 Aug 2025
NULL
Genpharmasec reports Profit after tax of 1.56 Crores, in the June 2025 quarter
ResultGENPHARMA7 Aug 2025
NULL
Genpharmasec - Quaterly Results
ResultGENPHARMA7 Aug 2025
NULL
Genpharmasec - Quaterly Results
ResultGENPHARMA7 Aug 2025
NULL
Genpharmasec acquires 70% stake in Derren Healthcare
Stock NewsGENPHARMA26 Jul 2025
The acquisition is done at a purchase consideration of Rs 34.15 crore
Genpharmasec reports Profit after tax of Rs -22.70 Lakhs, in the March 2025 quarter
ResultGENPHARMA21 May 2025
NULL
Genpharmasec - Quaterly Results
ResultGENPHARMA21 May 2025
NULL

